References
- Sutherland L R, Martin F, Greer S, et al. 5-Amino-salicylic acid enema in the treatment of distal ulcer-ative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92: 1894–1898
- Campieri M, Lanfranchi G A, Bazzocchi G, et al. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet 1981; 2: 270–271
- Hanauer S B, Kane S V, Guernsey B, et al. Randomized clinical trial of mesalazine (5ASA) enemas in distal ulerative colitis: a dose-ranging placebo controlled study ‘Abstract’. Gastroenterology 1989; 96: A195
- Willoughby C P, Campieri M, Lanfranchi G, Trulove S C, Jewell D P. 5-Aminosalicyclic acid (Pentasa) in enema form for the treatment of active ulcerative colitis. Ital J Gastroenterol 1986; 18: 15–17
- Danish 5-ASA Group. Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. Dig Dis Sci 1987; 32: 598–602
- Mulder C J J, Tytgat G N J, Wiltink E H H, Houthoff H-J. Comparison of 5-aminosalicylic acid (3 g) and prednisolone phosphate sodium enemas (30 mg) in the treatment of distal ulcerative colitis. Scand J Gastroenterol 1988; 23: 1005–1008
- van Hees P A M, Bakker J H, van Tongeren J H M. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sul-phasalazine. Gut 1980; 21: 632–635
- Williams C N, Haber G, Aquino J A. Double-blind, placebo controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories. Dig Dis Sci 1987; 32(suppl 12)71S–75S
- van Hogezand R A, van Hees P A M, van Gorp J P W M, et al. Double blind comparison of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid suppositories in patients with idiopathic proctitis. Aliment Pharmacol Ther 1988; 2: 33
- Campieri M, De Franchis R, Bianchi Porro G, Ranzi T, Brunetti G, Barbara L. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Scand J Gastroenterol 1990; 25: 663–638
- Khan Azad A K, Piris J, Truelove S C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; 2: 892–895
- Campieri M, Lanfranchi G A, Boschi S, et al. Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion. Gut 1985; 26: 400–405
- Dew M J, Cardwell M, Kidwai N S, Evans B K, Rhodes J. 5-Aminosalicylic acid in serum and urine after administration by enema to patients with colitis. J Pharm Pharmacol 1983; 35: 323–324
- Bondesen S, Nielsen Haagen O, Jacobsen O, et al. 5-Aminosalicylic acid enemas in patients with active ulcerative colitis. Influence of acidity on the kinetic pattern. Scand J Gastroenterol 1984; 19: 677–682
- Norlander B, Gotthard R, Ström M. Pharmaco-kinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form. Aliment Pharmacol Ther 1989; 3: 333–342
- Christensen L A, Fallingborg J, Abildgaard K, et al. Topical and systemic availability of 5-amino-salicylate: comparisons of three controlled release preparations in man. Aliment Pharmacol Ther 1990; 4: 523–533
- Hansen S H. Assay of 5-aminosalicylate and its acetylated metabolite in biological fluids by high performance liquid chromatography on dynamically modified silica. J Chromatogr 1981; 226: 504–509
- Sutherland L R. Topical treatment of ulcerative colitis. Med Clin North Am 1990; 74: 119–131
- Campieri M, Lanfranchi G A, Brignola C, et al. Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis. Dis Colon Rectum 1986; 29: 108–110